BrainsWay Ltd. (TLV:BWAY)
Israel · Delayed Price · Currency is ILS · Price in ILA | Market Cap | 1.39B +34.3% |
| Revenue (ttm) | 180.82M +31.7% |
| Net Income | 28.13M +76.7% |
| EPS | 0.68 +109.9% |
| Shares Out | 40.25M |
| PE Ratio | 50.61 |
| Forward PE | 31.66 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 169,663 |
| Open | 3,458.00 |
| Previous Close | 3,458.00 |
| Day's Range | 3,375.00 - 3,546.00 |
| 52-Week Range | 2,391.00 - 5,165.00 |
| Beta | 0.10 |
| Analysts | n/a |
| Price Target | n/a |
| Est. Earnings | Nov 11, 2026 |
About BrainsWay
BrainsWay Ltd. develops and sells noninvasive neurostimulation treatments for mental health disorders in the United States and internationally. It offers Deep Transcranial Magnetic Stimulation platform technology for the treatment of major depressive disorders, anxious and late-life depression, obsessive-compulsive disorders, smoking addiction, bipolar disorders, post-traumatic stress disorders, schizophrenia, Alzheimer’s disease, autism, chronic pain, multiple sclerosis, post stroke rehabilitation, and Parkinson’s diseases. The company serves ... [Read more]
Financial Performance
In 2025, BrainsWay's revenue was $52.23 million, an increase of 27.33% compared to the previous year's $41.02 million. Earnings were $7.58 million, an increase of 159.33%.
Financial numbers in USD Financial StatementsNews
BrainsWay Expands U.S. Insurance Coverage for Deep TMS Treatment of OCD to Over 118 Million Lives
BrainsWay Ltd. announced an expansion in the number of medical policies across the U.S. providing coverage for the use of BrainsWay Deep TMS in the treatment of patients suffering from obsessive compu...
BrainsWay Expands U.S. Insurance Coverage for Deep TMS™ Treatment of OCD to Over 118 Million Lives
BURLINGTON, Mass. and JERUSALEM, Oct. 26, 2026 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive brain stimulation techno...
BrainsWay - Depositary Receipt Price Target Increased by 218.89% to $0.20
The average one-year price target for BrainsWay - Depositary Receipt (NASDAQGM:BWAY) has been revised to $0.20 / share. This is an increase of 218.89% from the prior estimate of $0.06 dated October 1,...
BrainsWay Announces Strategic Collaboration with Inland Psychiatry Medical Group
Partnership with Established Southern California Behavioral Health Provider Aims to Accelerate Innovative Application of Interventional Psychiatry Treatments Partnership with Established Southern Cali...
A Look at BrainsWay Ltd (BWAY) After 4.0% Gain -- GF Value $7.30 vs Price $11.92
A Look at BrainsWay Ltd (BWAY) After 4.0% Gain -- GF Value $7.30 vs Price $11.92
Brainsway reports rise in Swift Accelerated Deep TMS protocol coverage
BrainsWay (BWAY) announced further expansion in the number of medical policies across the U.S. providing coverage for its Swift Accelerated Deep TMS protocol. With this update, there are now over…
BrainsWay Reports Rise in Favorable Accelerated Deep TMS™ Coverage to Over 70 Million Covered Lives
BURLINGTON, Mass. and JERUSALEM, Oct. 13, 2026 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive brain stimulation techno...
Brainsway publishes results from pilot study
BrainsWay (BWAY) announced the publication of results from a pilot study evaluating the company’s proprietary Deep Transcranial Magnetic Stimulation technology in patients with co-occurring Major Depr...
BrainsWay Reports Promising Pilot Study Results in Patients with Depression and Comorbid Early-Stage Alzheimer's Disease Treated with Deep TMS™
Peer-reviewed pilot study shows 83.3% response rate and 50% remission rate in depressive symptoms, alongside measurable neurophysiological changes in brain activity and connectivity
Brainsway price target raised to $19 from $17 at H.C. Wainwright
H.C. Wainwright analyst Raghuram Selvaraju raised the firm’s price target on Brainsway (BWAY) to $19 from $17 and keeps a Buy rating on the shares. The company’s Q2 financial results…
Brainsway reports Q2 EPS 7c, consensus 7c
Reports Q2 revenue $12.77M, consensus $16.54M. “This quarter marked our second consecutive quarter of approximately 35% revenue growth and further expansion in operating leverage. Revenue reached a re...
Brainsway raises FY26 revenue view to $68M-$70M from $66M-$68M
Consensus $67.65M. Narrows FY26 adjusted EBITDA view to $13M-$14M from $12M-$14M. “This quarter marked our second consecutive quarter of approximately 35% revenue growth and further expansion in opera...
Brainsway price target raised to $18.80 from $18 at Ladenburg
Ladenburg raised the firm’s price target on Brainsway (BWAY) to $18.80 from $18 and keeps a Buy rating on the shares post the Q2 report. The firm says the company’s…
Brainsway Q2 Earnings Call Highlights
Brainsway NASDAQ: BWAY reported second-quarter revenue growth of 35% and raised its full-year 2026 revenue outlook, citing continued demand for its Deep TMS systems, expanding reimbursement for its ac...
BrainsWay Earnings Call Transcript: Q2 2026
Q2 2026 saw 35% revenue growth, margin expansion, and strong recurring revenue visibility, driven by robust Deep TMS system demand and SWIFT protocol adoption. Full-year guidance was raised, supported by a growing backlog, strategic investments, and a debt-free balance sheet.
BrainsWay Earnings release: Q2 2026
BrainsWay released its Q2 2026 earnings on August 13, 2026, summarizing the period's financial results.
BrainsWay Reports Second Quarter 2026 Financial Results and Operational Highlights
Record s econd q uarter 2026 r evenue increased 35% t o $17. 1 m illion, compared with Q2 2025
BrainsWay Slides: Investor presentation
BrainsWay has posted slides in relation to its latest quarterly earnings report, which was published on August 1, 2026.
BrainsWay Announces Strategic Investment in Radial Health, Inc.
BrainsWay continues to actively evaluate similar investments in leading North American mental health providers to raise awareness and expand access to transformative care BrainsWay continues to active...
Brainsway initiated with a Buy at BTIG
BTIG initiated coverage of Brainsway (BWAY) with a Buy rating and $18 price target The company has demonstrated the ability to scale a transcranial magnetic stimulation business into sustainable profi...
BrainsWay Announces Minority-Stake Investment in Sound Minds Behavioral
Investment further supports BrainsWay's strategy of partnering with growth-oriented mental health providers to raise awareness and expand access to transformative care Investment further supports Brai...
Brainsway presents new Deep Transcranial Magnetic Stimulation data
BrainsWay (BWAY) announced the presentation of new real-world data demonstrating significant improvements in patients with comorbid post-traumatic stress disorder and Major Depressive Disorder treated...
BrainsWay Presents Positive Data from Largest Real-World Study of Deep TMS™ in Patients with Comorbid PTSD and Major Depressive Disorder
Nearly half of individuals diagnosed with PTSD also meet criteria for major depressive disorder (MDD), making comorbid depression one of the most common and clinically significant complications of PTS...
BrainsWay Reports Favorable Coverage for Accelerated Deep TMS™ Rises to Over 57 Million Covered Lives
BURLINGTON, Mass. and JERUSALEM, June 22, 2026 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive brain stimulation techno...
BrainsWay Presents First SWIFT™ Accelerated Deep TMS 12-Month Durability Data at Clinical TMS Society Annual Meeting
Preliminary Data Analysis Reveals Over 80% Remission Rate One Year after Accelerated Deep TMS Treatment, with Decline in Severe Functional Impairment from 85% to 0% Preliminary Data Analysis Reveals O...